Airway Therapeutics

ZELPULTIDE ALFA

A First-in-Class Biologic Designed to Modulate Inflammation and Facilitate Infection Clearance

OUR VISION

We envision a future where our immune-modulating therapies fundamentally change how we prevent and treat respiratory, inflammatory, and infectious diseases. Through our first-in-class biologic, zelpultide alfa, we aim to break the destructive cycle of dysregulated inflammation and infection by modulating immune responses at the source. Guided by science, we are building a platform that helps patients breathe easier, recover faster, and live longer, healthier lives, driving a global shift in the understanding and treatment of immune-driven conditions.

OUR IMPACT

Zelpultide alfa is a first-in-class recombinant protein that replicates the structure and function of native surfactant protein D (SP-D). Engineered to restore the body’s natural ability to modulate and reduce inflammation, and enhance infection clearance, it provides a preventive and therapeutic solution for a broad range of acute and chronic inflammatory and infectious diseases across all ages — from extremely preterm neonates to adults.

Learn more about Zelpultide Alfa

PRESS RELEASES

Airway Therapeutics Receives European Medicines Agency Pediatric Committee Approval for Zelpultide Alfa’s Study Plan in Bronchopulmonary Dysplasia for Very Preterm Infants

August 28, 2025

Multinational Phase 2b dose selection and Phase 3 expansion study for zelpultide alfa set to begin in late Q3/Q4 2025 MARIETTA, Ga., Aug. 12, 2025 /PRNewswire/ — Airway Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel biologic therapies for respiratory, inflammatory, and infectious diseases, today announced that the European Medicines Agency (EMA) Pediatric Committee (PDCO) has... full press release

Airway Therapeutics to Launch a Multinational Phase 3 Trial of Zelpultide Alfa for Preterm Neonates at Risk of Bronchopulmonary Dysplasia

October 15, 2024

Airway Therapeutics, Inc. (Airway), a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, announced today it will launch a multinational Phase 3 clinical trial in December 2024 of zelpultide alfa (rhSP-D) for prevention of bronchopulmonary dysplasia (BPD) and minimization of resulting lung damage in preterm infants.... full press release

Airway Therapeutics Wins 2024 ATS Whitsett Award for Abstract of Positive Phase 1b Results of Zelpultide Alfa in Preterm Neonates at Risk of Bronchopulmonary Dysplasia

June 24, 2024

Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, announced today it received the Whitsett Award for highest scoring abstracts from the Neonatal and Developing Lung Executive Committee at the American Thoracic Society (ATS) 2024 International Conference.... full press release